# Curoverse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curoverse

- Industry: Healthcare IT
- Headquarters: Boston, US
- Website: curoverse.com
- Total disclosed funding: $1.5M
- Latest round: Seed (Dec 18, 2013)
- Investors on record: 5

## About

Curoverse specializes in bioinformatics, providing an open-source platform that facilitates the management, processing, and analysis of large-scale biomedical datasets, catering specifically to genomics and imaging.Curoverse operates as a bioinformatics company focused on biomedical computing through its Arvados platform. Founded by Tom Clegg, the company is headquartered in Boston, US. The most recent funding was a Seed round in August 2017, securing USD 1.50 mn from investors including Converge Venture Partners and Hatteras Venture Partners. Curoverse has raised a total of USD 1.50 mn across its funding rounds.Curoverse's primary offering is Arvados, an open-source bioinformatics and biomedical computing platform designed to manage, process, analyze, and share large-scale biomedical datasets, particularly in genomics and imaging. Arvados integrates a content-addressable storage system with a containerized workflow engine to effectively handle data ranging from terabytes to petabytes, enabling research institutions and pharmaceutical companies to manage next-generation sequencing data efficiently. The platform is flexible, supporting deployment on various infrastructures, ensuring that client data remains under their control.Curoverse generates revenue primarily through subscription services for its Arvados platform, which includes custom implementation and support. Clients access the software through partnerships, resulting in revenue generation based on subscription tiers that cater to their specific needs, including the scale of cloud storage and computational resources utilized. Curoverse also offers trial periods, allowing prospective users to explore cloud storage and compute services before committing.Curoverse's strategy for future growth includes enhancing the Arvados platform with upcoming new features and functionalities aimed at improving user experience and efficiency in data management. The company is also targeting expansion into European markets to increase its client base by 2025. The recent Seed funding of USD 1.50 mn will support these initiatives, particularly in product development and market outreach. In August 2017, Veritas Genetics agreed to acquire Curoverse, aligning with the company’s strategic growth objectives.

## Funding rounds

- Seed, Dec 18, 2013, $1.5M — Hatteras Venture Partners, PJC, MassVentures, Converge Venture Partners, Hyperplane Venture Capital

## Investors

- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Seed
- PJC (https://capitalatlas.ai/funds/pjc) — Seed
- MassVentures (https://capitalatlas.ai/funds/massventures) — Seed
- Converge Venture Partners (https://capitalatlas.ai/funds/converge-venture-partners) — Seed
- Hyperplane Venture Capital (https://capitalatlas.ai/funds/hyperplane-venture-capital) — Seed